Drug Profile
Research programme - secretory immunoglobulin A - BioSavita
Alternative Names: Immunoglobulin A - BioSavita; Secretory IgA - BioSavita; Secretory immunoglobulin A - BioSavitaLatest Information Update: 29 Jan 2018
Price :
$50
*
At a glance
- Originator BioSavita
- Class Antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 29 Jan 2018 Technology for antibody discovery is available for licensing (http://biosavita.com/technology-licensing/)
- 29 Jan 2018 Discontinued for Clostridium difficile infections in USA (Parenteral) (BioSavita pipeline, Jaunaury 2018)
- 16 Jul 2016 No recent reports of development identified for research development in Clostridium difficile infections in USA (Parenteral)